Medifast
MED
263 hedge funds and large institutions have $1.03B invested in Medifast in 2022 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 89 increasing their positions, 96 reducing their positions, and 58 closing their positions.
2.2% more ownership
Funds ownership: 84.15% → 86.35% (+2.2%)
7% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 96
7% less funds holding
Funds holding: 284 → 263 (-21)
17% less call options, than puts
Call options by funds: $8.45M | Put options by funds: $10.1M
31% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 58
41% less capital invested
Capital invested by funds: $1.75B → $1.03B (-$717M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$19M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$15M |
| 3 |
CCM
Chimera Capital Management
New York
|
+$12.7M |
| 4 |
Millennium Management
New York
|
+$8.29M |
| 5 |
JP Morgan Chase
New York
|
+$7.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NPIC
Neumeier Poma Investment Counsel
Carmel,
California
|
-$37.4M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$23.7M |
| 3 |
GEH
General Equity Holdings
Brooklyn,
New York
|
-$15.8M |
| 4 |
Renaissance Technologies
New York
|
-$11M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$8.08M |
MED Hedge Fund Activity: Q3 2022 in Review
263 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Medifast (MED) for Q3 2022, worth a combined $1.03B — down 41% from $1.75B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of MED and 40 opened new positions — a net loss of 18 holders — while 96 trimmed existing stakes and 89 added.
The largest buyer was Morgan Stanley, adding an estimated $19M. The largest seller was Neumeier Poma Investment Counsel, exiting entirely with an estimated $37.4M sold.
- 263 institutional investors held Medifast (MED) as of Q3 2022, down from 284 in Q2 2022.
- Funds reported $1.03B of Medifast stock for Q3 2022, down 41% quarter-over-quarter.
- 40 funds opened new Medifast positions in Q3 2022 and 58 closed out, a net change of -18 holders.
- The largest Medifast buyer in Q3 2022 was Morgan Stanley, an estimated $19M added.
- The largest Medifast seller in Q3 2022 was Neumeier Poma Investment Counsel, an estimated $37.4M sold.
Based on aggregated 13F filings for Q3 2022.